Deals

Glaukos and STAAR Drive OIS Index into Record Territory

Glaukos and STAAR Drive OIS Index into Record Territory

The OIS Index of ophthalmic stocks surged to new highs in August, driven by two of the highest-weighted stocks in the index. The OIS Index gained 16.3% in August, while the overall US stock market, as measured by the Russell 3000 Index gained 3.3%, the NASDAQ Biotechnology Index gained 4.8%, and a composite of US…

Read More

OIS Index Lags Market Benchmarks in July

OIS Index

The OIS Index of ophthalmic stocks declined by 1.1% in July, against a strong overall market backdrop. During the month, the overall US stock market as measured by the Russell 3000 Index gained 3.9%, while the NASDAQ Biotechnology Index gained 8.6% and a composite of US medical device stocks gained 4.7%. Within the index, declining…

Read More

OIS Index Hits New Highs; Two New Companies Added

OIS Index Hits New Highs

The OIS Index stayed in four-digit territory in June, finishing the month at 1,017 and again outperforming its stock market benchmarks. The OIS Index gained 2.1% during the month, while the NASDAQ Biotechnology Index declined by 0.9%; the overall US stock market, as measured by the Russell 3000 Index, declined by 0.1%; and a composite…

Read More

What’s Next for Alcon Spin-off

What’s Next for Alcon Spin-off

As Novartis unveiled plans to spin off its Alcon eye care unit, the Swiss healthcare giant named Alcon CEO Mike Ball chairman-designate to guide the transformation of the Fort Worth, TX-based unit into a Swiss-based global device company. How much will the spin-off bring in? In the announcement, Novartis also said it would buy back…

Read More

Ophthalmic Stocks’ Rally Rolls Through April

Ophthalmic Stocks' Rally Rolls Through April

The OIS Index gained 5.2% in April, on the heels of a 4.4% gain in March. Ophthalmic stocks have far outperformed key market benchmarks over the past one and three months. The NASDAQ Biotechnology Index declined 3% in April, while the overall US stock market as measured by the Russell 3000 Index gained 0.3% and…

Read More

15 Things We Learned at OIS@ASCRS

Takeaways from OIS@ASCRS 2018

Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision accommodating intraocular lens implanted. The average objective accommodation at six months measured 2.00 diopters, he said. For the first time, Keranova presented preclinical results of its all-in-one cataract surgery platform.…

Read More

Lurker Describes Next Steps for EyePoint

Lurker Describes Next Steps for EyePoint

Within a week Nancy Lurker went from president and CEO of what had been known as an R&D company to the same title at a commercial specialty pharma company in the ophthalmology space, and she didn’t even have to change jobs. Lurker, who just guided the metamorphosis of pSivida into EyePoint Pharmaceuticals thanks to the…

Read More

41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging glaucoma therapies, the signature sessions on public market activity and “Masters of the Industry,” and a new panel on frontiers in femtosecond lasers. It’s all set for next Thursday, April…

Read More

OIS Index Outperforms Market in Another Volatile Month

OIS Index

The OIS Index gained 4.4% in March, far outperforming its key benchmarks during another volatile month for the markets. The NASDAQ Biotechnology Index declined by 1.3% in March, while the overall US stock market as measured by the Russell 3000 Index declined by 2.2%. A composite of US medical device stocks turned in a small…

Read More

OIS Index Follows Market Downward During a Rocky February

OIS Index Follows Market Downward During a Rocky February

The OIS Index declined by 4.2% in February, tracking stock market benchmarks during a volatile month. The NASDAQ Biotechnology Index suffered a slightly larger decline of 5.4%, while a composite of US medical device stocks and the overall US stock market as measured by the Russell 3000 Index declined by 3.9%. During February, both the…

Read More

OIS Index Delivers Small Gain, But Lags Benchmarks in January

In January, the OIS Index scratched out a small gain, but underperformed its relevant benchmarks. The OIS Index gained 0.3%, compared with gains of 7% for the NASDAQ Biotechnology Index, 10.2% for a composite of US medical device stocks, and 5.2% for the overall US stock market as measured by the Russell 3000 Index. Check…

Read More